Show simple item record

dc.contributor.authorHuri, Emreen_US
dc.contributor.authorBeyazit, Y.en_US
dc.contributor.authorMammadov, Rashaden_US
dc.contributor.authorToksoz, Sılaen_US
dc.contributor.authorTekinay, Ayşe B.en_US
dc.contributor.authorGüler, Mustafa O.en_US
dc.contributor.authorUstun H.en_US
dc.contributor.authorKekilli, M.en_US
dc.contributor.authorDadali, Mumtazen_US
dc.contributor.authorCelik, T.en_US
dc.contributor.authorAstarci, M.en_US
dc.contributor.authorHaznedaroglu I.C.en_US
dc.date.accessioned2016-02-08T09:40:04Z
dc.date.available2016-02-08T09:40:04Z
dc.date.issued2013en_US
dc.identifier.issn1687-8787
dc.identifier.urihttp://hdl.handle.net/11693/21039
dc.description.abstractPurpose. Using the classical Ankaferd Blood Stopper (ABS) solution to create active hemostasis during partial nephrectomy (PN) may not be so effective due to insufficient contact surface between the ABS hemostatic liquid agent and the bleeding area. In order to broaden the contact surface, we generated a chimeric hemostatic agent, ABS nanohemostat, via combining a self-assembling peptide amphiphile molecule with the traditional Ankaferd hemostat. Materials and Methods. In order to generate ABS nanohemostat, a positively charged Peptide Amphiphile (PA) molecule was synthesized by using solid phase peptide synthesis. For animal experiments, 24 Wistar rats were divided into the following 4 groups: Group 1: control; Group 2: conventional PN with only 0.5 ml Ankaferd hemostat; Group 3: conventional PN with ABS + peptide gel; Group 4: conventional PN with only 0.5 ml peptide solution. Results. Mean warm ischemia times (WITs) were 232.8 ± 56.3, 65.6 ± 11.4, 75.5 ± 17.2, and 58.1 ± 17.6 seconds in Group 1 to Group 4, respectively. Fibrosis was not different among the groups, while inflammation was detected to be significantly different in G3 and G4. Conclusions. ABS nanohemostat has comparable hemostatic efficacy to the traditional Ankaferd hemostat in the partial nephrectomy experimental model. Elucidation of the cellular and tissue effects of this chimeric compound may establish a catalytic spark and open new avenues for novel experimental and clinical studies in the battlefield of hemostasis. © 2013 Emre Huri et al.en_US
dc.language.isoEnglishen_US
dc.source.titleInternational Journal of Biomaterialsen_US
dc.relation.isversionofhttp://dx.doi.org/10.1155/2013/949460en_US
dc.titleGeneration of chimeric "aBS nanohemostat" complex and comparing its histomorphological in vivo effects to the traditional ankaferd hemostat in controlled experimental partial nephrectomy modelen_US
dc.typeArticleen_US
dc.departmentInstitute of Materials Science and Nanotechnology (UNAM)en_US
dc.departmentAysel Sabuncu Brain Research Center (BAM)en_US
dc.citation.volumeNumber2013en_US
dc.identifier.doi10.1155/2013/949460en_US
dc.publisherHindawien_US
dc.contributor.bilkentauthorHuri, Emre
dc.contributor.bilkentauthorMammadov, Rashad
dc.contributor.bilkentauthorToksoz, Sıla
dc.contributor.bilkentauthorTekinay, Ayşe B.
dc.contributor.bilkentauthorGüler, Mustafa O.
dc.contributor.bilkentauthorDadali, Mumtaz


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record